Global Secondary Progressive Multiple Sclerosis Drug market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031. Get Access Now!

Global Secondary Progressive Multiple Sclerosis Drug Market Size and Outlook 2025-31

The global Secondary Progressive Multiple Sclerosis Drug market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031. The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs. Infinity Market Research newest research report, the Secondary Progressive Multiple Sclerosis Drug Industry Forecast looks at past sales and reviews total world Secondary Progressive Multiple Sclerosis Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Secondary Progressive Multiple Sclerosis Drug sales for 2025 through 2031. With Secondary Progressive Multiple Sclerosis Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Secondary Progressive Multiple Sclerosis Drug industry. This Insight Report provides a comprehensive analysis of the global Secondary Progressive Multiple Sclerosis Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Secondary Progressive Multiple Sclerosis Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Secondary Progressive Multiple Sclerosis Drug market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Secondary Progressive Multiple Sclerosis Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Secondary Progressive Multiple Sclerosis Drug. This report presents a comprehensive overview, market shares, and growth opportunities of Secondary Progressive Multiple Sclerosis Drug market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; Inebilizumab &nbsp;&nbsp;&nbsp; GLX-1112 &nbsp;&nbsp;&nbsp; DC-TAB &nbsp;&nbsp;&nbsp; Etomoxir &nbsp;&nbsp;&nbsp; IB-MS &nbsp;&nbsp;&nbsp; Others Segmentation by Application: &nbsp;&nbsp;&nbsp; Hospital &nbsp;&nbsp;&nbsp; Clinic &nbsp;&nbsp;&nbsp; Others This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; AB Science SA &nbsp;&nbsp;&nbsp; Actelion Ltd &nbsp;&nbsp;&nbsp; Biogen, Inc. &nbsp;&nbsp;&nbsp; F. Hoffmann-La Roche Ltd. &nbsp;&nbsp;&nbsp; Genzyme Corporation &nbsp;&nbsp;&nbsp; Glialogix, Inc. &nbsp;&nbsp;&nbsp; Immune Response BioPharma, Inc. &nbsp;&nbsp;&nbsp; Innate Immunotherapeutics Ltd &nbsp;&nbsp;&nbsp; Kyorin Pharmaceutical Co., Ltd. &nbsp;&nbsp;&nbsp; Mallinckrodt Plc &nbsp;&nbsp;&nbsp; MedDay SA &nbsp;&nbsp;&nbsp; MedImmune, LLC &nbsp;&nbsp;&nbsp; Merck KGaA &nbsp;&nbsp;&nbsp; Meta-IQ ApS &nbsp;&nbsp;&nbsp; Novartis AG &nbsp;&nbsp;&nbsp; Opexa Therapeutics, Inc. &nbsp;&nbsp;&nbsp; Xenetic Biosciences (UK) Limited Key Questions Addressed in this Report What is the 10-year outlook for the global Secondary Progressive Multiple Sclerosis Drug market? What factors are driving Secondary Progressive Multiple Sclerosis Drug market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Secondary Progressive Multiple Sclerosis Drug market opportunities vary by end market size? How does Secondary Progressive Multiple Sclerosis Drug break out by Type, by Application?

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Secondary Progressive Multiple Sclerosis Drug Annual Sales 2020-2031 &nbsp;2.1.2 World Current & Future Analysis for Secondary Progressive Multiple Sclerosis Drug by Geographic Region, 2020, 2024 & 2031 &nbsp;2.1.3 World Current & Future Analysis for Secondary Progressive Multiple Sclerosis Drug by Country/Region, 2020, 2024 & 2031 &nbsp;2.2 Secondary Progressive Multiple Sclerosis Drug Segment by Type &nbsp;2.2.1 Inebilizumab &nbsp;2.2.2 GLX-1112 &nbsp;2.2.3 DC-TAB &nbsp;2.2.4 Etomoxir &nbsp;2.2.5 IB-MS &nbsp;2.2.6 Others &nbsp;2.3 Secondary Progressive Multiple Sclerosis Drug Sales by Type &nbsp;2.3.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2020-2025) &nbsp;2.3.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue and Market Share by Type (2020-2025) &nbsp;2.3.3 Global Secondary Progressive Multiple Sclerosis Drug Sale Price by Type (2020-2025) &nbsp;2.4 Secondary Progressive Multiple Sclerosis Drug Segment by Application &nbsp;2.4.1 Hospital &nbsp;2.4.2 Clinic &nbsp;2.4.3 Others &nbsp;2.5 Secondary Progressive Multiple Sclerosis Drug Sales by Application &nbsp;2.5.1 Global Secondary Progressive Multiple Sclerosis Drug Sale Market Share by Application (2020-2025) &nbsp;2.5.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue and Market Share by Application (2020-2025) &nbsp;2.5.3 Global Secondary Progressive Multiple Sclerosis Drug Sale Price by Application (2020-2025) 3 Global by Company &nbsp;3.1 Global Secondary Progressive Multiple Sclerosis Drug Breakdown Data by Company &nbsp;3.1.1 Global Secondary Progressive Multiple Sclerosis Drug Annual Sales by Company (2020-2025) &nbsp;3.1.2 Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Company (2020-2025) &nbsp;3.2 Global Secondary Progressive Multiple Sclerosis Drug Annual Revenue by Company (2020-2025) &nbsp;3.2.1 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Company (2020-2025) &nbsp;3.2.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Company (2020-2025) &nbsp;3.3 Global Secondary Progressive Multiple Sclerosis Drug Sale Price by Company &nbsp;3.4 Key Manufacturers Secondary Progressive Multiple Sclerosis Drug Producing Area Distribution, Sales Area, Product Type &nbsp;3.4.1 Key Manufacturers Secondary Progressive Multiple Sclerosis Drug Product Location Distribution &nbsp;3.4.2 Players Secondary Progressive Multiple Sclerosis Drug Products Offered &nbsp;3.5 Market Concentration Rate Analysis &nbsp;3.5.1 Competition Landscape Analysis &nbsp;3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.6 New Products and Potential Entrants &nbsp;3.7 Market M&A Activity & Strategy 4 World Historic Review for Secondary Progressive Multiple Sclerosis Drug by Geographic Region &nbsp;4.1 World Historic Secondary Progressive Multiple Sclerosis Drug Market Size by Geographic Region (2020-2025) &nbsp;4.1.1 Global Secondary Progressive Multiple Sclerosis Drug Annual Sales by Geographic Region (2020-2025) &nbsp;4.1.2 Global Secondary Progressive Multiple Sclerosis Drug Annual Revenue by Geographic Region (2020-2025) &nbsp;4.2 World Historic Secondary Progressive Multiple Sclerosis Drug Market Size by Country/Region (2020-2025) &nbsp;4.2.1 Global Secondary Progressive Multiple Sclerosis Drug Annual Sales by Country/Region (2020-2025) &nbsp;4.2.2 Global Secondary Progressive Multiple Sclerosis Drug Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Secondary Progressive Multiple Sclerosis Drug Sales Growth &nbsp;4.4 APAC Secondary Progressive Multiple Sclerosis Drug Sales Growth &nbsp;4.5 Europe Secondary Progressive Multiple Sclerosis Drug Sales Growth &nbsp;4.6 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales Growth 5 Americas &nbsp;5.1 Americas Secondary Progressive Multiple Sclerosis Drug Sales by Country &nbsp;5.1.1 Americas Secondary Progressive Multiple Sclerosis Drug Sales by Country (2020-2025) &nbsp;5.1.2 Americas Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2020-2025) &nbsp;5.2 Americas Secondary Progressive Multiple Sclerosis Drug Sales by Type (2020-2025) &nbsp;5.3 Americas Secondary Progressive Multiple Sclerosis Drug Sales by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Secondary Progressive Multiple Sclerosis Drug Sales by Region &nbsp;6.1.1 APAC Secondary Progressive Multiple Sclerosis Drug Sales by Region (2020-2025) &nbsp;6.1.2 APAC Secondary Progressive Multiple Sclerosis Drug Revenue by Region (2020-2025) &nbsp;6.2 APAC Secondary Progressive Multiple Sclerosis Drug Sales by Type (2020-2025) &nbsp;6.3 APAC Secondary Progressive Multiple Sclerosis Drug Sales by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia &nbsp;6.10 China Taiwan 7 Europe &nbsp;7.1 Europe Secondary Progressive Multiple Sclerosis Drug by Country &nbsp;7.1.1 Europe Secondary Progressive Multiple Sclerosis Drug Sales by Country (2020-2025) &nbsp;7.1.2 Europe Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2020-2025) &nbsp;7.2 Europe Secondary Progressive Multiple Sclerosis Drug Sales by Type (2020-2025) &nbsp;7.3 Europe Secondary Progressive Multiple Sclerosis Drug Sales by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug by Country &nbsp;8.1.1 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales by Country (2020-2025) &nbsp;8.1.2 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2020-2025) &nbsp;8.2 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales by Type (2020-2025) &nbsp;8.3 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Manufacturing Cost Structure Analysis &nbsp;10.1 Raw Material and Suppliers &nbsp;10.2 Manufacturing Cost Structure Analysis of Secondary Progressive Multiple Sclerosis Drug &nbsp;10.3 Manufacturing Process Analysis of Secondary Progressive Multiple Sclerosis Drug &nbsp;10.4 Industry Chain Structure of Secondary Progressive Multiple Sclerosis Drug 11 Marketing, Distributors and Customer &nbsp;11.1 Sales Channel &nbsp;11.1.1 Direct Channels &nbsp;11.1.2 Indirect Channels &nbsp;11.2 Secondary Progressive Multiple Sclerosis Drug Distributors &nbsp;11.3 Secondary Progressive Multiple Sclerosis Drug Customer 12 World Forecast Review for Secondary Progressive Multiple Sclerosis Drug by Geographic Region &nbsp;12.1 Global Secondary Progressive Multiple Sclerosis Drug Market Size Forecast by Region &nbsp;12.1.1 Global Secondary Progressive Multiple Sclerosis Drug Forecast by Region (2026-2031) &nbsp;12.1.2 Global Secondary Progressive Multiple Sclerosis Drug Annual Revenue Forecast by Region (2026-2031) &nbsp;12.2 Americas Forecast by Country (2026-2031) &nbsp;12.3 APAC Forecast by Region (2026-2031) &nbsp;12.4 Europe Forecast by Country (2026-2031) &nbsp;12.5 Middle East & Africa Forecast by Country (2026-2031) &nbsp;12.6 Global Secondary Progressive Multiple Sclerosis Drug Forecast by Type (2026-2031) &nbsp;12.7 Global Secondary Progressive Multiple Sclerosis Drug Forecast by Application (2026-2031) 13 Key Players Analysis &nbsp;13.1 AB Science SA &nbsp;13.1.1 AB Science SA Company Information &nbsp;13.1.2 AB Science SA Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications &nbsp;13.1.3 AB Science SA Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.1.4 AB Science SA Main Business Overview &nbsp;13.1.5 AB Science SA Latest Developments &nbsp;13.2 Actelion Ltd &nbsp;13.2.1 Actelion Ltd Company Information &nbsp;13.2.2 Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications &nbsp;13.2.3 Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.2.4 Actelion Ltd Main Business Overview &nbsp;13.2.5 Actelion Ltd Latest Developments &nbsp;13.3 Biogen, Inc. &nbsp;13.3.1 Biogen, Inc. Company Information &nbsp;13.3.2 Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications &nbsp;13.3.3 Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.3.4 Biogen, Inc. Main Business Overview &nbsp;13.3.5 Biogen, Inc. Latest Developments &nbsp;13.4 F. Hoffmann-La Roche Ltd. &nbsp;13.4.1 F. Hoffmann-La Roche Ltd. Company Information &nbsp;13.4.2 F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications &nbsp;13.4.3 F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.4.4 F. Hoffmann-La Roche Ltd. Main Business Overview &nbsp;13.4.5 F. Hoffmann-La Roche Ltd. Latest Developments &nbsp;13.5 Genzyme Corporation &nbsp;13.5.1 Genzyme Corporation Company Information &nbsp;13.5.2 Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications &nbsp;13.5.3 Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.5.4 Genzyme Corporation Main Business Overview &nbsp;13.5.5 Genzyme Corporation Latest Developments &nbsp;13.6 Glialogix, Inc. &nbsp;13.6.1 Glialogix, Inc. Company Information &nbsp;13.6.2 Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications &nbsp;13.6.3 Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.6.4 Glialogix, Inc. Main Business Overview &nbsp;13.6.5 Glialogix, Inc. Latest Developments &nbsp;13.7 Immune Response BioPharma, Inc. &nbsp;13.7.1 Immune Response BioPharma, Inc. Company Information &nbsp;13.7.2 Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications &nbsp;13.7.3 Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.7.4 Immune Response BioPharma, Inc. Main Business Overview &nbsp;13.7.5 Immune Response BioPharma, Inc. Latest Developments &nbsp;13.8 Innate Immunotherapeutics Ltd &nbsp;13.8.1 Innate Immunotherapeutics Ltd Company Information &nbsp;13.8.2 Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications &nbsp;13.8.3 Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.8.4 Innate Immunotherapeutics Ltd Main Business Overview &nbsp;13.8.5 Innate Immunotherapeutics Ltd Latest Developments &nbsp;13.9 Kyorin Pharmaceutical Co., Ltd. &nbsp;13.9.1 Kyorin Pharmaceutical Co., Ltd. Company Information &nbsp;13.9.2 Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications &nbsp;13.9.3 Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.9.4 Kyorin Pharmaceutical Co., Ltd. Main Business Overview &nbsp;13.9.5 Kyorin Pharmaceutical Co., Ltd. Latest Developments &nbsp;13.10 Mallinckrodt Plc &nbsp;13.10.1 Mallinckrodt Plc Company Information &nbsp;13.10.2 Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications &nbsp;13.10.3 Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.10.4 Mallinckrodt Plc Main Business Overview &nbsp;13.10.5 Mallinckrodt Plc Latest Developments &nbsp;13.11 MedDay SA &nbsp;13.11.1 MedDay SA Company Information &nbsp;13.11.2 MedDay SA Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications &nbsp;13.11.3 MedDay SA Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.11.4 MedDay SA Main Business Overview &nbsp;13.11.5 MedDay SA Latest Developments &nbsp;13.12 MedImmune, LLC &nbsp;13.12.1 MedImmune, LLC Company Information &nbsp;13.12.2 MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications &nbsp;13.12.3 MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.12.4 MedImmune, LLC Main Business Overview &nbsp;13.12.5 MedImmune, LLC Latest Developments &nbsp;13.13 Merck KGaA &nbsp;13.13.1 Merck KGaA Company Information &nbsp;13.13.2 Merck KGaA Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications &nbsp;13.13.3 Merck KGaA Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.13.4 Merck KGaA Main Business Overview &nbsp;13.13.5 Merck KGaA Latest Developments &nbsp;13.14 Meta-IQ ApS &nbsp;13.14.1 Meta-IQ ApS Company Information &nbsp;13.14.2 Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications &nbsp;13.14.3 Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.14.4 Meta-IQ ApS Main Business Overview &nbsp;13.14.5 Meta-IQ ApS Latest Developments &nbsp;13.15 Novartis AG &nbsp;13.15.1 Novartis AG Company Information &nbsp;13.15.2 Novartis AG Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications &nbsp;13.15.3 Novartis AG Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.15.4 Novartis AG Main Business Overview &nbsp;13.15.5 Novartis AG Latest Developments &nbsp;13.16 Opexa Therapeutics, Inc. &nbsp;13.16.1 Opexa Therapeutics, Inc. Company Information &nbsp;13.16.2 Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications &nbsp;13.16.3 Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.16.4 Opexa Therapeutics, Inc. Main Business Overview &nbsp;13.16.5 Opexa Therapeutics, Inc. Latest Developments &nbsp;13.17 Xenetic Biosciences (UK) Limited &nbsp;13.17.1 Xenetic Biosciences (UK) Limited Company Information &nbsp;13.17.2 Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications &nbsp;13.17.3 Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.17.4 Xenetic Biosciences (UK) Limited Main Business Overview &nbsp;13.17.5 Xenetic Biosciences (UK) Limited Latest Developments 14 Research Findings and Conclusion

Report	Global Secondary Progressive Multiple Sclerosis Drug Market Growth 2025-2031
Selected License	Multi ID: LPI23765

Buyer Information

Order Summary